KUALA LUMPUR: Among the reasons why Singapore was ahead of Malaysia in procuring Covid-19 vaccines was because Temasek Holdings and other investors had invested US$250mil (RM1.06bil) into German biotech company BioNTech, says Khairy Jamaluddin.
The Science, Technology and Innovation Minister said it was likely that Singapore was prioritised by BioNTech, which developed the Pfizer-BioNTech Covid-19 vaccine in a joint venture with Pfizer, because Temasek Holdings has a stake in the company.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
